Table 1.
Clinical, pathologic, and molecular characteristics of EFPVTC and NFVPTC
| No. of patients (%) | |||
|---|---|---|---|
| Characteristic | EFPVTC (n=22) | NFVPTC (n=19) | P-valuea |
| Age | |||
| Median (years) | 47 | 52 | 0.51 |
| ≤ 45 | 9 (41) | 5 (26) | |
| > 45 | 13 (59) | 14 (74) | |
| Gender | 0.47 | ||
| Female | 16 (73) | 16 (84) | |
| Male | 6 (27) | 3 (16) | |
| Tumor size (cm) | |||
| Median | 1.7 | 0.9 | 0.49 |
| ≤ 4 | 20 (91) | 19 (100) | |
| > 4 | 2 (9) | 0 (0) | |
| Vascular invasion | 1 | ||
| Absent | 21 (95) | 18 (95) | |
| Present | 1 (5) | 1 (5) | |
| Extrathyroid extension | 1 | ||
| Absent | 22 (100) | 19 (100) | |
| Present | 0 (0) | 0 (0) | |
| Central nodal metastases | 1 | ||
| Absent | 22 (100) | 19 (100) | |
| Present | 0 (0) | 0 (0) | |
| Thyroid surgery | 0.42 | ||
| Lobectomy | 5 (23) | 2 (11) | |
| Total thyroidectomy +/− CLNDb | 17 (77) | 17 (89) | |
| BRAF V600E mutation | 0.59 | ||
| Absent | 21 (95) | 17 (89) | |
| Present | 1 (5) | 2 (11) | |
| RAS mutations c | 0.49 | ||
| Absent | 20 (90) | 19 (100) | |
| Present | 2 (10) | 0 (0) | |
a
Fisher’s exact test, two-tailed values
b
Central lymph node dissection
c
RAS mutations assessed include H-RAS, K-RAS, and N-RAS at codons 12, 13, and 61